Welcome to the new ACTG Precautionary and Prohibited Medications Database

Printer-friendly versionPrinter-friendly version
What is the Role for the ACTG Precautionary and Prohibited Medications Database?
The ACTG Precautionary and Prohibited Medications Database was created to assist investigators and research staff during protocol development and the conduct of clinical studies to access the most current pharmacokinetic data on drug interactions with antiretrovirals. The drug interactions are divided into a Precautionary Medications and a Prohibited Medications section. In order to gain more experience with the data in this database, users are also encouraged to complete the Clinical Pharmacology Tutorial that is provided through the University at Buffalo HIV Clinical Pharmacology Quality Assurance Program (https://www.fstrf.org/CPQA)
This website will assist HIV researchers developing a protocol or conducting a protocol to:
  1. Identify the important medications that must be avoided during the screening process as well as after the subject is enrolled.
  2. Identify the precautionary medications that should be monitored closely in subjects entering the protocol or after the subject is receiving the study treatment.
  3. Access recent drug interaction data that has been presented at HIV research conferences but are not published yet.

How Do I Use This Website?

Investigators may use the "Search" box on the top right hand corner or the "Search" hyperlink across the top bar.  In the "Search" Box please type in a medication name to obtain a list of associated prohibited or precautionary medications. A glossary is included as keyword reference for users.

What is the Mechanism that is used to create the ACTG Precautionary and Prohibited Medications Database?
Contributor Panel: These panel members are usually Doctor of Pharmacy students, post-doctoral residents or fellows. Drug interactions data from abstracts from key HIV conferences are reviewed and a summary is submitted through a secure website portal.
Editorial Panel: These panel members are established HIV researchers with expertise in clinical pharmacology and drug interactions. Using an online mechanism, similar to most journal review websites, the summaries are reviewed and either accepted or submitted for editing. After approval the abstract summary is then available to the Database Manager.
Database Manager: The Database Manager reviews the summary for completeness and comments by the expert panel members. The summary is then published on the database for access by investigators through the report feature of the website.